RxDoctor Payments Data

Keith Robinson, MD

Internal Medicine · Aurora, ILNPI 1619950680

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Sunovion Pharmaceuticals Inc. accounts for 60.2% of it on its own, with 6 other manufacturers making up the rest.

$403in general payments, 2019–2025

Across 9 payments — averaging $44.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$243
  • Pfizer$44
  • Lilly USA, LLC$26
  • Boehringer Ingelheim$26
  • Phathom Pharmaceuticals, Inc.$25
  • Agios Pharmaceuticals, Inc.$21
  • plus $19 from 1 others
$30,165in research payments, 2019–2025

Across 5 payments — averaging $6033.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$30K

What the payments were for

  • Food & beverage$403100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$403 in reported general payments places this provider in the 65th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois →

Medicare billing

Part B allowed, 2024
$191,470
Medicare patients
484
Services billed
2,297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban24$13,536
Enoxaparin Sodium11$1,714
Atorvastatin Calcium45$396
Oxcarbazepine11$381
Pantoprazole Sodium33$231
Gabapentin19$180
Oxycodone Hcl22$103
Metoprolol Succinate17$88
Losartan Potassium14$66
Amlodipine Besylate20$63
Lisinopril14$39
Furosemide12$31
Metoprolol Tartrate12$23

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$44$13,53624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Aurora

See the full list for Illinois →

Where these figures come from

Is this you, or does something look wrong? →